Overview

Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003

Status:
Completed
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and efficacy of CNTO 136 (sirukumab) in participants with rheumatoid arthritis (RA) who are unresponsive to treatment with modifying antirheumatic drugs (DMARDs) or anti-TNF alpha agents.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Collaborator:
GlaxoSmithKline
Treatments:
Antibodies, Monoclonal